Welcome to our dedicated page for IceCure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. director Huang Yang filed an initial ownership report detailing equity holdings in the company. The filing shows 111,468 restricted stock units (RSUs) granted on May 15, 2025, with 41,800 vested and 69,668 unvested as of March 18, 2026.
Huang also holds several fully vested share options over ordinary shares, including 25,000 options at an exercise price of $1.70 per share expiring in December 2030 and 80,668 options at $3.64 per share expiring in January 2032, plus an additional option grant at $1.51 per share expiring in February 2033.
IceCure Medical Ltd. director Chan Vincent Chun Hung filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider such as a director or large shareholder. This filing reports no transactions and no share movements; it is purely an ownership disclosure record at this stage.
IceCure Medical Ltd. executive Tel-Tzure Tlalit Bussi, VP of BD & Global Marketing, reports her initial ownership position. As of March 18, 2026, she beneficially owns 170,629 ordinary shares and restricted share units. She also holds multiple share option grants over ordinary shares at exercise prices ranging from $0.92 to $5.78, with expirations between 2029 and 2034, many of which are fully vested.
IceCure Medical Ltd. Chief Operating Officer Levav Shay filed an initial ownership report showing direct holdings of 144,615 ordinary shares plus several option grants. These options cover 50,000 shares at an exercise price of $1.56, 385 shares at $5.78, 80,668 shares at $3.64, 4,084 shares at $2.84, 40,705 shares at $1.51, and 98,182 shares at $0.92, with expirations ranging from 2030 to 2034. Footnotes state that some grants are already fully vested, while others vest in quarterly installments. In addition, Shay has unvested restricted share units of 81,818, 43,416 and 19,381 units from awards dated July 2, 2024, November 5, 2025 and March 16, 2026, respectively, all unvested as of March 18, 2026.
IceCure Medical Ltd. director Sharon Levita filed an initial insider ownership report on Form 3. The provided data shows no reportable transactions or derivative positions included in this filing.
IceCure Medical Ltd. executive Good Shad, VP Sales for North America, filed an initial statement of ownership showing 156,455 ordinary shares, composed of 6,578 shares and multiple RSU grants that remained unvested as of March 18, 2026. He also holds options to buy 50,000 ordinary shares at $1.22 per share expiring on August 14, 2033, and options on 72,756 ordinary shares at $0.92 per share expiring on July 2, 2034, with portions of each option grant already vested by that date.
IceCure Medical Ltd. Chief Financial Officer Ronen Tsimerman filed an initial Form 3 disclosing his equity holdings in the company. As of March 18, 2026, he holds 16,257 ordinary shares and 161,692 unvested restricted share units that vest over time under two RSU grants.
He also reports multiple share option awards over several years, covering tens of thousands of underlying ordinary shares at exercise prices ranging from $0.79 to $5.78 per share, with expiration dates extending from 2027 through 2034. Many of these options are fully vested, while some continue to vest in quarterly installments.
IceCure Medical Ltd. director Mayron Ron filed an initial Form 3, detailing existing equity holdings rather than new trades. Ron holds 296,631 ordinary shares, consisting of 10,000 shares and 286,631 restricted share units, of which 107,486 have vested and 179,631 remain unvested as of March 18, 2026.
Ron also reports several fully vested share option grants over the company’s ordinary shares: 95,295 options at an exercise price of $1.55 per share expiring in 2028, 25,000 at $1.79 expiring in 2029, 25,000 at $1.68 expiring in 2030, and 110,000 at $3.64 expiring in 2032. An additional 59,295 options at $1.51 per share expiring in 2033 are partly vested, with 44,471 options vested as of March 18, 2026. This filing simply records Ron’s current ownership position.
IceCure Medical Ltd. officer Naum Muchnik, VP of R&D & Engineering, reports his current equity holdings in the company. He holds 118,621 ordinary shares directly, with no buy or sell transactions reported in this filing.
He also holds multiple option grants over ordinary shares, including 4,142 options at an exercise price of $2.27 per share expiring in 2029, 16,000 options at $1.79 expiring in 2029, 27,462 options at $1.56 expiring in 2030, 1,318 options at $5.78 expiring in 2031, 80,668 options at $3.64 expiring in 2032, 4,085 options at $2.84 expiring in 2032, 40,705 options at $1.51 expiring in 2033, and 90,945 options at $0.92 expiring in 2034.
Footnotes state that earlier grants are fully vested as of March 18, 2026, while more recent option and restricted share unit awards vest over time, with portions already vested and the remainder scheduled to vest in equal quarterly installments.
IceCure Medical Ltd. VP of Human Resources Dotan Merav Nir filed a Form 3 disclosing existing equity holdings in the company. The filing shows direct ownership of 68,814 ordinary shares, made up of 500 shares and 68,314 unvested restricted stock units granted in 2024, 2025, and 2026 as of March 18, 2026.
Nir also holds share options over 80,668 ordinary shares at an exercise price of $3.64 per share fully vested and expiring in 2032, 40,705 options at $1.51 expiring in 2033, and 27,283 options at $0.92 expiring in 2034. The Form 3 records these positions only, with no reported purchases or sales.